Sibutramine and its cardiovascular profile

Sibutramine : review of its cardiovascular risk-benefit profile

Sibutramine on Cardiovascular Outcome

S ibutramine, a combined norepinephrine and serotonin reuptake inhibitor, is effective in the management of obese patients requiring pharmacotherapy as part of a multimodal approach to weight loss. It improves insulin resistance markers, glucose metabolism, and atherogenic dyslipidemia in both diabetic and nondiabetic patients, most of these effects resulting fromweight loss. However, sibutrami...

Cardiovascular Safety Pharmacology of Sibutramine

Sibutramine is an anorectic that has been banned since 2010 due to cardiovascular safety issues. However, counterfeit drugs or slimming products that include sibutramine are still available in the market. It has been reported that illegal sibutramine-contained pharmaceutical products induce cardiovascular crisis. However, the mechanism underlying sibutramine-induced cardiovascular adverse effec...

The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients

Moderate weight loss improves metabolic and cardiovascular risk factors and prevents the progression to Type 2 diabetes. Furthermore, a healthy lifestyle is associated with lower cardiovascular mortality, whereas sustained weight loss and increased fitness are both associated with reduced cardiovascular mortality. Currently available antiobesity drugs have been shown to deliver moderate weight ...

Paradoxical effect of sibutramine on autonomic cardiovascular regulation.

BACKGROUND Sibutramine, a serotonin and norepinephrine transporter blocker, is widely used as an adjunctive obesity treatment. Norepinephrine reuptake inhibition with sibutramine conceivably could exacerbate arterial hypertension and promote cardiovascular disease. METHODS AND RESULTS In 11 healthy subjects (7 men, age 27+/-2 years, body mass index 23.1+/-0.7 kg/m2), we compared the effect of...